Lataa...
Short and long-term effects of CDK4/6 inhibition on early stage breast cancer
CDK4/6 inhibitors are used in the treatment of advanced estrogen receptor (ER)(+) breast cancer (BC). Their efficacy in ER(−) and early stage BC is currently under investigation. Here, we show that palbociclib, a CDK4/6 inhibitor, can inhibit both progression of ductal carcinoma in situ (DCIS) and g...
Tallennettuna:
| Julkaisussa: | Mol Cancer Ther |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6891167/ https://ncbi.nlm.nih.gov/pubmed/31451564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0231 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|